Catalyst Dossier · compiled by CeliA 🧫

ASTRAZENECA PLC (AZNCF)

Biotechnology · market cap $290.6B · as of 2026-07-08

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-07-31 (est.)

Phase 2

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Non-US-listed company. Financial statements and forensic scores here come from US SEC filings (10-K/10-Q), which foreign issuers don’t file — those sections may be blank. The catalyst calendar, pipeline, approval odds, price context and (where covered) analyst targets still apply.

AstraZeneca PLC (AZNCF) is a large-cap global biopharmaceutical company with approximately 94,300 employees and a market capitalization of roughly $290.6 billion. The company operates an exceptionally broad pipeline spanning oncology, cardiovascular, respiratory, metabolic disease, and immunology, with multiple Phase 3 assets including Osimertinib (NSCLC), Camizestrant (breast cancer), Capivasertib (TNBC), and several other late-stage programs. Key near-term catalysts include high-importance Phase 3 readouts for Osimertinib and Camizestrant in early-to-mid 2027.

The catalyst path

2026-07-31 (est.)Phase 2 · Zibotentan/Dapagliflozinimp 7/10
2027-01-11 (est.)Phase 3 · AZD0780imp 9/10
2027-01-18 (est.)Phase 2 · Durvalumabimp 7/10
2027-02-11 (est.)Phase 2 · AZD4144imp 7/10
2027-02-22 (est.)Phase 3 · Osimertinibimp 9/10
2027-04-20 (est.)Phase 3 · Camizestrantimp 9/10
2027-04-20 (est.)Phase 2 · AZD5148imp 7/10
2027-06-15 (est.)Phase 2 · Acalabrutinib monotherapyimp 7/10

Pipeline

Asset	Phase	Indication
CIN-107 2 mg dosing	Phase 2	Primary Aldosteronism
Simvastatin	Phase 3	Hypercholesterolemia
MEDI4736 + Tremelimumab	Phase 2	Recurrent/Metastatic Squamous Cell Carcinoma of Head & Neck
Paroxetine	Phase 3	Generalized Anxiety Disorder
AZD2265	Phase 3	Metastatic Castration-resistant Prostate Cancer
MEDI3250	Phase 3	Healthy Japanese Children Age 2 Years Through 6 Years
abiraterone acetate	Phase 3	Metastatic Castration-resistant Prostate Cancer
Capivasertib	Phase 3	Triple Negative Breast Neoplasms
Metformin IR	Phase 3	Diabetes Mellitus, Type 2
Formoterol (OT)	Phase 3	Chronic Obstructive Pulmonary Disease
Tomudex	Phase 2	Inoperable or Recurrent Rectal Cancer
fostamatinib	Phase 3	Rheumatoid Arthritis
Arimidex 1 mg	Phase 2	McCune-Albright Syndrome
AZD0837	Phase 2	Persistent or Permanent Non-valvular Atrial Fibrillation
fluticasone	Phase 3	Asthma
Aclidinium bromide/formoterol Fixed-Dose Combination (FDC)	Phase 3	Chronic Obstructive Pulmonary Disease
Anastrozole	Phase 3	Breast Neoplasms
Roflumilast	Phase 3	Asthma
AZD7798	Phase 2	Moderate to Severe Crohn's Disease
metformin	Phase 3	Type 2 Diabetes Mellitus

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for AZNCF (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.